Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DARATUMUMAB Cause Electrocardiogram qt prolonged? 29 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 29 reports of Electrocardiogram qt prolonged have been filed in association with DARATUMUMAB (DARZALEX). This represents 0.1% of all adverse event reports for DARATUMUMAB.

29
Reports of Electrocardiogram qt prolonged with DARATUMUMAB
0.1%
of all DARATUMUMAB reports
3
Deaths
14
Hospitalizations

How Dangerous Is Electrocardiogram qt prolonged From DARATUMUMAB?

Of the 29 reports, 3 (10.3%) resulted in death, 14 (48.3%) required hospitalization.

Is Electrocardiogram qt prolonged Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DARATUMUMAB. However, 29 reports have been filed with the FAERS database.

What Other Side Effects Does DARATUMUMAB Cause?

Plasma cell myeloma (2,980) Infusion related reaction (2,557) Off label use (2,494) Pneumonia (1,450) Neutropenia (1,351) Drug ineffective (1,110) Thrombocytopenia (1,089) Death (1,088) Pyrexia (1,032) Dyspnoea (996)

What Other Drugs Cause Electrocardiogram qt prolonged?

QUETIAPINE (1,869) OLANZAPINE (1,325) RIBOCICLIB (1,020) AMIODARONE (1,000) HYDROXYCHLOROQUINE (992) CLOZAPINE (958) CITALOPRAM HYDROBROMIDE (917) ESCITALOPRAM OXALATE (899) ONDANSETRON (881) BUPROPION (853)

Which DARATUMUMAB Alternatives Have Lower Electrocardiogram qt prolonged Risk?

DARATUMUMAB vs DARATUMUMAB\HYALURONIDASE-FIHJ DARATUMUMAB vs DARBEPOETIN ALFA DARATUMUMAB vs DARIDOREXANT DARATUMUMAB vs DARIFENACIN HYDROBROMIDE DARATUMUMAB vs DAROLUTAMIDE

Related Pages

DARATUMUMAB Full Profile All Electrocardiogram qt prolonged Reports All Drugs Causing Electrocardiogram qt prolonged DARATUMUMAB Demographics